Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheridan

Showing results (31-40 of 7,538) with videos related to

Pageof 754
Sort By:
Nature Biotechnology|June 11, 2009
Vaccine market boostersCormac Sheridan
Nature Biotechnology|September 9, 2016
Merck stakes out 'irritable' neuron territory with $1.25 billionCormac Sheridan
Nature Biotechnology|June 8, 2017
Interest rekindles in drug cocktails that reprogram cellsCormac Sheridan
Nature Biotechnology|July 7, 2018
Merck vaccine heads Ebola countermeasuresCormac Sheridan
Nature Biotechnology|October 2, 2003
EMEA struggles with need to restructureCormac Sheridan
Nature Biotechnology|November 5, 2003
Benefits of biotech clusters questionedCormac Sheridan
Nature Biotechnology|December 4, 2003
Germany biotech gets second chanceCormac Sheridan
Nature Biotechnology|November 9, 2007
Big oil's biomass playCormac Sheridan
Nature Biotechnology|August 9, 2008
EGFR inhibitors embrace KRASCormac Sheridan
Nature Biotechnology|March 10, 2015
Amgen's bispecific antibody puffs across finish lineCormac Sheridan
Pageof 754

Showing results (31-40 of 7,538) with videos related to

Sort By:
Pageof 754
Nature Biotechnology|June 11, 2009
Vaccine market boostersCormac Sheridan
Nature Biotechnology|September 9, 2016
Merck stakes out 'irritable' neuron territory with $1.25 billionCormac Sheridan
Nature Biotechnology|June 8, 2017
Interest rekindles in drug cocktails that reprogram cellsCormac Sheridan
Nature Biotechnology|July 7, 2018
Merck vaccine heads Ebola countermeasuresCormac Sheridan
Nature Biotechnology|October 2, 2003
EMEA struggles with need to restructureCormac Sheridan
Nature Biotechnology|November 5, 2003
Benefits of biotech clusters questionedCormac Sheridan
Nature Biotechnology|December 4, 2003
Germany biotech gets second chanceCormac Sheridan
Nature Biotechnology|November 9, 2007
Big oil's biomass playCormac Sheridan
Nature Biotechnology|August 9, 2008
EGFR inhibitors embrace KRASCormac Sheridan
Nature Biotechnology|March 10, 2015
Amgen's bispecific antibody puffs across finish lineCormac Sheridan
Pageof 754